+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

General pharmacological properties of the new angiotensin II receptor antagonist (+/-)-1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl) biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylate. Part I: Effects on central nervous system and other properties



General pharmacological properties of the new angiotensin II receptor antagonist (+/-)-1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl) biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylate. Part I: Effects on central nervous system and other properties



Arzneimittel-Forschung 46(6): 572-579



The effects of TCV-116 ((+/-)-1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl) biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylate, CAS 145040-37-5), a nonpeptide angiotensin II receptor antagonist, on the central nervous and autonomic nervous systems, isolated smooth muscle and digestive system were investigated in various experimental animals. TCV-116 at 1000 mg/kg (p.o.) produced a slight decrease in body tone in mice, but at 300 mg/kg did not affect spontaneous locomotor activity, skeletal muscle coordination, tonic extensor convulsions, pentobarbital-induced sleeping time, frequency of acetic acid-induced writhing, or body temperature in mice or rats. TCV-116 (at 300 mg/kg p.o.) did not affect the spontaneous EEG in conscious, unrestrained cats, or (at 100 mg/kg i.d.) the spinal reflex in anesthetized cats. CV-11974, the active metabolite of TCV-116, did not inhibit neuromuscular transmission in isolated rat phrenic nerve-diaphragm preparations (10(-5) mol/l and 10(-4) mol/l). In anesthetized cats, TCV-116 at 100 and 300 mg/kg (i.d.) slightly reduced the pressor response to carotid occlusion, but had no effect on the bradycardic response to stimulation of the cervical vagus nerve, contraction of the nictitating membrane induced by electrical stimulation of the cervical sympathetic preganglionic nerve, or the changes in blood pressure in response to acetylcholine, histamine, norepinephrine, or bradykinin. CV-11974 had no effect on agonist-induced contraction of guinea pig ileum. In isolated smooth muscle preparations, CV-11974 even at 10(-4) mol/l did not affect the spontaneous motility of the rabbit ileum or the rat uterus, or KCl-induced tension in guinea pig trachea. TCV-116 at 300 mg/kg (p.o.) had no significant effect on gastric emptying or intestinal transport of a semisolid meal in rats, or on gastric secretion in pylorus-ligated rats. TCV-116 (30-300 mg/kg p.o.) had no effect on carrageenin-induced paw edema in rats. The results suggest that TCV-116 exerts no notable pharmacological effects on the central nervous system, autonomic nervous system, gastrointestinal function or smooth muscle function.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 046157579

Download citation: RISBibTeXText

PMID: 8767346


Related references

General pharmacological properties of the new angiotensin II receptor antagonist (racemic)-1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)-1H-benzimidazole-7-carboxylate. Part I. Effects on central nervous system and other properties. Arzneimittel Forschung 46(6): 572-579, 1996

General pharmacological properties of the new angiotensin II receptor antagonist (+/-)-1-(cyclohexyloxycarbonyloxy) ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl) biphenyl-4-yl] methyl]-1 H-benzimidazole-7-carboxylate. Part II: Effect on cardiovascular system and renal functions. Arzneimittel-Forschung 46(7): 681-686, 1996

General pharmacological properties of the new angiotensin II receptor antagonist (racemic)-1-(Cyclohexyloxycarbonyloxy) ethyl 2-ethoxy-1-((2'-(1H-tetrazol-5-yl) biphenyl-4-yl) methyl)-1H-benzimidazole-7-carboxylate: Part II: Effect on cardiovascular system and renal functions. Arzneimittel Forschung 46(7): 681-686, 1996

Pharmacological profile of a highly potent and long-acting angiotensin II receptor antagonist, 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4- yl]methyl]-1H-benzimidazole-7-carboxylic acid (CV-11974), and its prodrug, (+/-)-1-(cyclohexyloxycarbonyloxy)-ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5- yl)biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylate (TCV-116). Journal of Pharmacology and Experimental Therapeutics 266(1): 114-120, 1993

Antihypertensive effects of a highly potent and long-acting angiotensin II subtype-1 receptor antagonist, (+-)-1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H- benzimidazole-7-carboxylate (TCV-116), in various hypertensive rats. Journal of Pharmacology and Experimental Therapeutics 268(3): 1540-1547, 1994

Antihypertensive effects of a highly potent and long-acting angiotensin II subtype-1 receptor antagonist, -1- ethyl 2-ethoxy-1- bipenyl-4-yl-methyl-1H-benzimidazole-7-carboxylate. Journal of Pharmacology & Experimental Therapeutics 268(3): 1540-1547, 1994

The angiotensin receptor antagonist 2-ethoxy-1-[[2'-(1H- tetrazol-5-yl) biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylic acid (CV11974) attenuates the tubuloglomerular feedback response during NO synthase blockade in rats. Journal of Pharmacology and Experimental Therapeutics 277(2): 572-577, 1996

Pharmacological profile of a highly potent and long-acting angiotensin II receptor antagonist, 2-ethoxy-1 biphenyl-4-yl-1H-benzimidazole-7-carboyxlic acid. Journal of Pharmacology & Experimental Therapeutics 266(1): 114-120, 1993

Effects of the new angiotensin receptor antagonist dipotassium (Z)-2-((5-ethyl-3-(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl-1,3,4-thiadiazoline-2-ylidene)aminocarbonyl)-1-cyclopentencarboxylate on experimental cardiac hypertrophy and acute left ventricular failure. Arzneimittel Forschung 47(10): 1099-1103, 1997

Effects of the new angiotensin receptor antagonist dipotassium (Z)-2-[[5-ethyl-3-[2'-(1H-tetrazol-5-yl)biphenyl-4-yl] methyl-1,3,4-thiadiazoline-2-ylidene]aminocarbonyl]-1-cy clopentencarbox ylate on experimental cardiac hypertrophy and acute left ventricular failure. Arzneimittel-Forschung 47(10): 1099-1103, 1997

The angiotensin receptor antagonist 2-ethoxy-1- biphenyl-4-ylmethyl-1H-benzimidazole-7-carboxylic acid. Journal of Pharmacology & Experimental Therapeutics 277(2): 572-577, 1996

General pharmacological properties of cilostazol, a new antithrombotic drug. Part I: Effects on the central nervous system. Arzneimittel-Forschung 35(7a): 1157-1162, 1985

Effects of chlordiazepoxide training dose on the mixed agonist antagonist properties of ro 15 1788 ethyl 8 fluoro 5 6 dihydro 5 methyl 6 oxo 4h imidazo1 5a 1 4benzodiazepine 3 carboxylate a benzodiazepine receptor antagonist in a drug discrimination procedure. Neuroscience Letters (SUPPL 18): S118, 1984

A non-peptide angiotensin II receptor antagonist: 2-butyl-6-dimethoxymethyl-5-phenyl-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4- yl]methyl]-1H-imidazo[5,4-b]pyridine. Acta Crystallographica. Section C, Crystal Structure Communications 52: 1019-1022, 1996

Sodium [2'-[(cyclopropanecarbonyl-ethyl-amino)-methyl]-4'-(6-ethoxy-pyridin-3-yl)-6-methoxy-biphenyl-3-yl]-acetate (AM432): a potent, selective prostaglandin D2 receptor antagonist. Bioorganic and Medicinal Chemistry Letters 21(3): 1036-1040, 2011